Patents by Inventor Michael Horstmann

Michael Horstmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11612571
    Abstract: The invention relates to a transdermal therapeutic system for the controlled release of water-soluble pharmaceutical active ingredients from an aqueous phase, comprising an occlusive back layer, a central device facing the skin for releasing the agent, an adhesive layer concentrically surrounding the dispensing device and a removable protective film. Said device is made from a stationary solid phase and a liquid phase containing the active ingredient in aqueous solution, the solid phase being formed from a solid with a fleecy or spongy structure.
    Type: Grant
    Filed: January 19, 2008
    Date of Patent: March 28, 2023
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Bodo Asmussen, Michael Horstmann, Christoph Schmitz, Mohammad Sameti, Yves-Thorsten Przybylla, Rolf Pracht
  • Patent number: 11291745
    Abstract: Adhesive bandages are provided with a water-vapor permeable back layer and an adhesive layer, in which the adhesive layer includes 10 weight percent of a disperse internal phase of hydrophilic particles that are water-swellable in an outer phase that includes at least 10 weight percent of a styrene block copolymer and at least 20 weight percent of an ester resin of colophony, and that can further contain at least one anti-virus substance.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: April 5, 2022
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Horstmann, Christian Hausen, Patrick Mohr, Karin Ludwig, Tobias Kleudgen
  • Patent number: 10881607
    Abstract: The invention relates to a composition for transdermal delivery, particularly iontophoretic transdermal delivery, of at least one cationic active agent or a salt thereof. The composition includes at least one cationic active agent or a salt thereof, at least one polyamine or/and polyamine salt, water or an aqueous solvent mixture, and optionally one or more additives. The invention further relates to the use of such composition as a component of a transdermal patch or of an iontophoretic transdermal patch, as well as to the use of such composition in a method for transdermally and/or iontophoretically administering cationic active agents. The invention further includes methods for determining the in vitro skin permeation properties of an active-agent-containing iontophoretic composition.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: January 5, 2021
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Christoph Schmitz, Mohammad Sameti, Andreas Koch, Michael Horstmann
  • Patent number: 10881606
    Abstract: A composition for transdermal delivery, particularly iontophoretic transdermal delivery, having at least one cationic active agent or a salt thereof. The composition comprises at least one cationic active agent or a salt thereof, at least one polyamine and/or polyamine salt, water or an aqueous solvent mixture, and optionally one or more additives. Use of the composition as a component of a transdermal patch or of an iontophoretic transdermal patch is also provided, as well as the use of the composition in a method for transdermally or iontophoretically administering cationic active agents. A method for determining the in vitro skin permeation properties of an active agent-containing iontophoretic composition is also provided.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: January 5, 2021
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Christoph Schmitz, Mohammad Sameti, Andreas Koch, Michael Horstmann
  • Patent number: 10772845
    Abstract: The invention relates to a transdermal therapeutic system (TTS) which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system incorporates a back layer and an active substance-containing layer that includes at least one peptide and a carrier substance.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: September 15, 2020
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Horstmann, Horst Dzekan, Sandra Wiedersberg
  • Publication number: 20200179666
    Abstract: The invention relates to an adapter system comprising a frame and a lid that supports an active ingredient pad and serves to close said frame, the active ingredient pad being inserted into the frame in an operating position. The frame and the lid are interconnected force-fittingly and/or form-fittingly when in the operating position. The present invention makes it possible to position the active ingredient pad with precision.
    Type: Application
    Filed: August 8, 2018
    Publication date: June 11, 2020
    Inventors: Michael HORSTMANN, Roman HADASCHIK, Uwe WORTMANN
  • Publication number: 20200113819
    Abstract: The invention relates to a composition for transdermal delivery, particularly iontophoretic transdermal delivery, of at least one cationic active agent or a salt thereof. The composition includes at least one cationic active agent or a salt thereof, at least one polyamine or/and polyamine salt, water or an aqueous solvent mixture, and optionally one or more additives. The invention further relates to the use of such composition as a component of a transdermal patch or of an iontophoretic transdermal patch, as well as to the use of such composition in a method for transdermally and/or iontophoretically administering cationic active agents. The invention further includes methods for determining the in vitro skin permeation properties of an active-agent-containing iontophoretic composition.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 16, 2020
    Inventors: Christoph SCHMITZ, Mohammad SAMETI, Andreas KOCH, Michael HORSTMANN
  • Patent number: 10596126
    Abstract: The present invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that further include micronized or nanoscale active ingredient particles.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: March 24, 2020
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Horstmann, Mohammad Sameti, Tobias Jung
  • Patent number: 10471021
    Abstract: The invention relates to a transdermal therapeutic system (TTS), which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system includes a back layer and an active substance-containing layer that contains at least one peptide and a carrier substance, preferably as a textile web material.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 12, 2019
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Horstmann, Gerd Hoffmann, Sandra Wiedersberg
  • Publication number: 20190328680
    Abstract: The present invention provides transdermal therapeutic systems for dispensing a pharmaceutical product, in particular a pharmaceutical product with a low tendency to spontaneously crystallize. The matrix layer or at least one of the matrix layers in said systems contains a silicone hot-melt adhesive, a pharmaceutical product, and particles made of crosslinked polyvinylpyrrolidone. The invention also relates to a method for producing said transdermal therapeutic systems.
    Type: Application
    Filed: July 8, 2019
    Publication date: October 31, 2019
    Applicant: LTS Lohmann Therapie Systeme AG
    Inventors: Horst Dzekan, Hans-Rainer Hoffman, Michael Horstmann, Walter Müller, Sandra Wiedersberg
  • Publication number: 20190298662
    Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 3, 2019
    Inventors: René EIFLER, Michael HORSTMANN, Regine KAUFMANN, Patrick MOHR, Eric GALIA, Wolfgang PRANGE, Stefan BULLER, Klaus PUSECKER, Jan STAMPFUSS, Susanne STOELBEN
  • Publication number: 20190240166
    Abstract: The invention relates to a transdermal therapeutic system that includes a back layer that is impermeable to an active ingredient; a polymer matrix containing the active ingredient and a protective layer that can be pulled off. The active ingredient is 5-aminolevulinic acid hydrochloride and the basic polymer of the polymer matrix is an adhesive polyacrylate. The inventive transdermal therapeutic systems are suitable for diagnosing and treating preliminary stages of skin cancer, such as actinic keratosis, and oncological skin diseases.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 8, 2019
    Inventors: Tobias JUNG, Michael HORSTMANN, Gerd HOFFMANN
  • Publication number: 20190231710
    Abstract: The present invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that further include micronized or nanoscale active ingredient particles.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 1, 2019
    Inventors: Michael HORSTMANN, Mohammad SAMETI, Tobias JUNG
  • Patent number: 10363228
    Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: July 30, 2019
    Assignees: LTS Lohmann Therapie-Systeme AG, Gruenenthal GmbH
    Inventors: René Eifler, Michael Horstmann, Regine Kaufmann, Patrick Mohr, Eric Galia, Wolfgang Prange, Stefan Buller, Klaus Pusecker, Jan Stampfuss, Susanne Stoelben
  • Publication number: 20190192506
    Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 27, 2019
    Applicant: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Thomas Hille, Michael Horstmann, Walter Mueller
  • Patent number: 10315020
    Abstract: A device with a positioning frame which can be adhered onto the skin and with a transdermal therapeutic system which can be inserted into a cut-out that passes through the positioning frame. The active substance dispensing outlet side of the inserted transdermal therapeutic system facing the skin. The device includes a tool unit which can be inserted into the cut-out of the positioning frame and centered in said cut-out in order to produce openings at least in the uppermost layer of the skin.
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: June 11, 2019
    Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Uwe Wortmann, Roman Hadaschik, Michael Horstmann
  • Patent number: 10307382
    Abstract: The invention relates to a transdermal therapeutic system, comprising a back layer that is impermeable to an active ingredient, a polymer matrix containing the active ingredient, and a protective layer that can be pulled off, wherein 5-aminolevulinic acid hydrochloride is used as the active ingredient and the basic polymer of the polymer matrix is an adhesive polyacrylate. Said transdermal therapeutic system is suitable for diagnosing and treating preliminary stages of skin cancer, such as actinic keratosis, and oncological skin diseases.
    Type: Grant
    Filed: August 24, 2012
    Date of Patent: June 4, 2019
    Assignee: Photonamic GmbH & Co. KG
    Inventors: Tobias Jung, Michael Horstmann, Gerd Hoffmann
  • Patent number: 10292942
    Abstract: The invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that further include micronized or nanoscale active ingredient particles.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: May 21, 2019
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Horstmann, Mohammad Sameti, Tobias Jung
  • Publication number: 20190134254
    Abstract: The present invention relates to adhesive bandages provided with a water-vapor permeable back layer and an adhesive layer, in which the adhesive layer includes 10 weight percent of a disperse internal phase of hydrophilic particles that are water-swellable in an outer phase that includes at least 10 weight percent of a styrene block copolymer and at least 20 weight percent of an ester resin of colophony, and that can further contain at least one anti-virus substance.
    Type: Application
    Filed: January 4, 2019
    Publication date: May 9, 2019
    Inventors: Michael HORSTMANN, Christian HAUSEN, Patrick MOHR, Karin LUDWIG, Tobias KLEUDGEN
  • Publication number: 20180289698
    Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.
    Type: Application
    Filed: June 8, 2018
    Publication date: October 11, 2018
    Applicant: PURDUE PHARMA L.P.
    Inventors: Thomas Hille, Michael Horstmann, Walter Mueller